Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Melanoma

Christine Guo Lian,Yufei Xu,Craig Ceol,Feizhen Wu,Allison Larson,Karen Dresser,Wenqi Xu,Li Tan,Yeguang Hu,Qian Zhan,Chung-wei Lee,Di Hu,Bill Q. Lian,Sonja Kleffel,Yijun Yang,James Neiswender,Abraham J. Khorasani,Rui Fang,Cecilia Lezcano,Lyn M. Duncan,Richard A. Scolyer,John F. Thompson,Hojabr Kakavand,Yariv Houvras,Leonard I. Zon,Martin C. Mihm,Ursula B. Kaiser,Tobias Schatton,Bruce A. Woda,George F. Murphy,Yujiang G. Shi

DOI: https://doi.org/10.1016/j.cell.2012.07.033

IF: 64.5

2012-01-01

Cell

Abstract:DNA methylation at the 5 position of cytosine (5-mC) is a key epigenetic mark that is critical for various biological and pathological processes. 5-mC can be converted to 5-hydroxymethylcytosine (5-hmC) by the ten-eleven translocation (TET) family of DNA hydroxylases. Here, we report that "loss of 5-hmC" is an epigenetic hallmark of melanoma, with diagnostic and prognostic implications. Genome-wide mapping of 5-hmC reveals loss of the 5-hmC landscape in the melanoma epigenome. We show that downregulation of isocitrate dehydrogenase 2 (IDH2) and TET family enzymes is likely one of the mechanisms underlying 5-hmC loss in melanoma. Rebuilding the 5-hmC landscape in melanoma cells by reintroducing active TET2 or IDH2 suppresses melanoma growth and increases tumor-free survival in animal models. Thus, our study reveals a critical function of 5-hmC in melanoma development and directly links the IDH and TET activity-dependent epigenetic pathway to 5-hmC-mediated suppression of melanoma progression, suggesting a new strategy for epigenetic cancer therapy.